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Background: We report our experience in 49 consecutive patients with nasopharyngeal carcinoma who were
treated by Intensity-modulated radiation therapy (IMRT) combined with simultaneous but not adjuvant
chemotherapy (CHT).
Methods: The medical records of 49 patients with histologically proven primary nasopharygeal carcinoma treated
with IMRT and concurrent platin-based CHT (predominantly cisplatin weekly) were retrospectively reviewed. The
majority of patients showed advanced clinical stages (stage III/IV:72%) with undifferentiated histology (82%). IMRT
was performed in step-and-shoot technique using an integrated boost concept in 84%. In this concept, the boost
volume covered the primary tumor and involved nodes with doses of 66–70.4 Gy (single dose 2.2 Gy). Uninvolved
regional nodal areas were covered with doses of 54–59.4 Gy (median single dose 1.8 Gy). At least one parotid
gland was spared. None of the patients received adjuvant CHT.
Results: The median follow-up for the entire cohort was 48 months. Radiation therapy was completed without
interruption in all patients and 76% of the patients received at least 80% of the scheduled CHT. Four local
recurrences have been observed, transferring into 1-, 3-, and 5-year Local Control (LC) rates of 98%, 90% and 90%.
One patient developed an isolated regional nodal recurrence, resulting in 1-, 3-, and 5-year Regional Control (RC)
rates of 98%. All locoregional failures were located inside the radiation fields. Distant metastases were found in six
patients, transferring into 1-, 3, and 5-year Distant Control (DC) rates of 92%, 86% and 86%. Progression free survival
(PFS) rates after 1, 3 and 5 years were 86%, 70% and 69% and 1-, 3- and 5-year Overall Survival (OS) rates were 96%,
82% and 79%. Acute toxicity≥ grade III mainly consisted of dysphagia (32%), leukopenia (24%), stomatitis (16%),
infection (8%) and nausea (8%). Severe late toxicity (grade III) was documented in 18% of the patients, mainly as
xerostomia (10%).
Conclusion: Concurrent chemoradiation without the addition of adjuvant chemotherapy cycles using IMRT with an
integrated boost concept yielded good disease control and overall survival in patients suffering from primary
nasopharyngeal cancer with acceptable acute side effects and limited rates of late toxicity.
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Since the report of the Intergroup 0099 trial in 1998 by
Al-Sarraf et al. [1], which showed a survival benefit with
the addition of concurrent and adjuvant chemotherapy
to radiation alone, and the confirmation of their results
by several subsequent randomized trials and meta-
analyses [2-7], concurrent chemoradiation has emerged
as the standard of care at least for locally advanced
stages of nasopharyngeal cancer. However, with regard
to the still considerable rates of acute and late toxicities
and the limited treatment compliance using this com-
bination approach, some questions remain in terms of
radiation technique, fractionation and especially value
and timing of the adjuvant chemotherapy component.
For example, intensity-modulated radiation therapy
(IMRT) offers advantages in terms of target coverage or
sparing of organs at risk compared to the frequently
used conventional (2D-RT) or three-dimensional con-
formal (3D-RT) radiation techniques [8-10]. IMRT also
simply allows a slightly accelerated fractionation in the
boost areas (integrated boost). Encouraging results for
IMRT with low toxicity have been reported in several
single-center series [11-14]. Further on, many studies
[1-3,15,16] investigating combined chemoradiation,
also used adjuvant cycles of chemotherapy. This part of
the treatment was associated with considerable toxicity,
frequently not completed in a substantial proportion of
patients, and a recently published randomised trial found
no benefit for the addition of adjuvant chemotherapy
cycles compared to concurrent chemoradiation alone [17].
Thus, some concerns have been raised about the
need for additional adjuvant chemotherapy cycles,
especially when modern radiotherapy techniques like
IMRT are combined with simultaneous chemothe-
rapy. Here we report our retrospective analysis of 49
consecutive patients over a 10-year period using a
treatment approach consisting of IMRT with inte-
grated boost combined with concurrent but not adjuvant
platin-based chemotherapy. The data show that this
approach is effective with limited toxicity.
Methods
Patient characteristics
We identified a total of 55 patients with primary naso-
pharyngeal cancer in the database of the German Cancer
Research Center (DKFZ), who have been treated with
IMRT and concurrent chemotherapy at our institution
between 1999 and 2008. Data was obtained retrospect-
ively by chart and radiation therapy documentation re-
view. Six patients were excluded from analysis, because
they had received also adjuvant chemotherapy. All
patients suffered from histologically proven primary
nasopharyngeal cancer without evidence for distant me-
tastasis. Initial work-up included clinical and laboratoryexaminations, computed tomography (CT) and/or mag-
netic resonance imaging (MRI) of the head and neck
region, endoscopy with histological confirmation, chest
x-ray or CT, abdominal ultrasound or CT and bone scan
for exclusion of distant metastases. The patients were
staged according to the 6th edition of the International
union against cancer (UICC) TNM classification. Histo-
logical diagnosis was graded according to the world
health organisation (WHO) classification for nasopharyn-
geal cancer. 17 patients had a surgical intervention before
referral to our department, mainly as single lymph node
exstirpation or selective neck dissection for diagnostic rea-
sons. Two of them had incomplete local excisions. All
patients had measurable gross disease at the beginning of
concurrent chemoradiation. For detailed patient character-
istics, see Table 1.
Radiation therapy
External beam radiotherapy (EBRT) was performed in
intensity-modulated technique in all patients, using a step-
and-shoot approach. The technique of IMRT used in our
institution has been previously described [18,19]. Briefly, all
patients were fixed in an individually manufactured preci-
sion head mask made of Scotch castW (3 M, St.Paul,
Minneapolis, MN) and a vacuum pillow for the body. With
this immobilization system attached to the stereotactic base
frame, contrast-enhanced CT- and MRI-images were
performed with a slice thickness of at least 3 mm and fused
based on the localizer-derived coordinate system. The gross
tumor volume (GTV) was defined as the macroscopic
tumor defined after correlative analysis of CT- and MRI-
scans. In 59% of the patients additional GTVs were needed
to cover involved nodes. For the clinical target volume
(CTV) a margin of 0.5-1 cm was added manually to the
GTV. A second CTV was defined including the bilateral
uninvolved regional nodes (retro- and parapharyngeal
nodes, cervical nodes Level II-V and supraclavicular nodes).
A safety margin of 3–5 mm for the PTVs was added manu-
ally. Margins could be reduced in case of directly adjacent
organs at risk. Inverse treatment-planning was performed
using the KonRad and VIRTOUS software developed at the
German Cancer Research Center (DKFZ). EBRT was deliv-
ered by a linear accelerator with 6 or 15 MV photons using
an integrated motorized multileaf collimator (MLC) for the
step-and-shoot technique automatically delivering the
sequences. Since the introduction of a kV-CT on rails at
our institution in 2002, all patients received image guidance
(with the possibility for replanning if necessary) at least
once a week. The total doses were prescribed to the median
of the target volume and usually the 95% isodose sur-
rounded the PTV. An integrated boost concept was used in
the majority of patients (84%). According to this concept,
the boost volume (primary tumor and involved nodes), was
covered with doses of 66 to 70.4 Gy (median single dose
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Age [years], T, N and clinical stage according to 6th edition of the International
Union against Cancer (UICC) TNM classification, histology according to world
health organisation (WHO) classification, Cis: Cisplatin, Carbo: Carboplatin, 5-
FU: 5-Fluorouracil, n: number of patients,%: percentage of the entire cohort,
CHT: concurrent chemotherapy.
Figure 1 Example of dose distribution (frontal view, integrated
boost concept, prescribed dose 70.4 Gy = 100% in 32 fractions,
dotted line : 95% isodose, sparing of both parotid glands
and larynx).
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regions were covered with doses of 54–59.4 Gy (median
single dose 1.8 Gy). An example of a three dimensional
dose distribution illustrating this concept is shown in
Figure 1. At least one parotid gland was spared. For detailed
information about the dose constraints see Table 2. Inpatients with sequential boost concept, conventional frac-
tionation (single dose 1.8 to 2 Gy) was used.Chemotherapy
All patients received chemotherapy concurrently to EBRT.
The chemotherapy schedules varied over time, but were
platin-based in 97% of the patients. The majority of the
patients (63%) was scheduled for 6 cycles of weekly cis-
platin at a dose of 40 mg per square meter body surface.
Three patients had been treated with induction chemother-
apy before referral to our department but none of the
patients in this analysis received adjuvant chemotherapy.
For detailed treatment characteristics see Table 1.Follow up
Regular follow up visits were performed at our institution
or the referring center. At our institution, patients were
scheduled for follow up visits every three months for the
first two years, every 6 months for the three following years
and annually thereafter. Each follow-up visit included at
least clinical examination and CT or MRI of the head and
neck region. In case of evidence for locoregional recurrence
or distant spread, additional tests or imaging modalities
were performed to confirm or exclude disease progression
at the discretion of the treating physician. Missing data
were completed by calling the patient or the treating
physician.
Table 2 Dose constraints
Dose constraints Max [Gy] Mean [Gy]










*: in cases with involved nodes in the supraclavicular region, doses up to
66 Gy were tolerated in small regions, °: in case of T4 lesions, doses up to
66 Gy were tolerated in small regions, ‘: at least one parotid gland was
restricted to a median dose of 26 Gy, Max : Maximum dose to the organ at
risk, Mean : Mean dose to the organ at risk, Gy : Gray.
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Figure 2 Local control.
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Local control (LC) was defined as absence of tumor (re)-
growth in the region of the primary tumor. Regional con-
trol (RC) was defined as absence of tumor (re)-growth in
the bilateral cervical nodal areas. Distant control (DC) was
defined as absence of distant metastases. In patients with-
out further assessment of local/regional control, for
example after development of distant spread, the date of
the last information about the local/regional status was
used for calculation. Progression free survival (PFS) was
defined as absence of disease progression at any site or
death of any cause. Acute and late side effects were
reported as documented in the patient charts. Acute
toxicity was scored according to Common Toxicity Criteria
version 3.0 (CTCAE V3.0) from the start of radiation ther-
apy until 3 months of follow up. Late toxicity was scored
according to CTCAE 3.0 thereafter until the end of follow-
up. If multiple occurrence was documented, the most
severe grade of a specific event was used for grading.
Disease related functional impairments present prior to the
start of chemoradiation were scored as toxicity only if wor-
sening occurred. Xerostomia was scored as subjectively
assessed by the patients and graded according to Radiation
Therapy Oncology Group (RTOG)/European Organization
for Research and Treatment (EORTC) radiation morbidity
scoring criteria [20].
Statistical methods
Time to event data was calculated from the first day of radi-
ation treatment until the last follow up information or until
death using the Kaplan-Meier method. Categorical variables
were compared by Fisher’s exact test. Differences were con-
sidered statistically significant for a p-value of ≤ 0.05. The
study is in compliance with the Declaration of Helsinki
(Sixth Revision, 2008). Furthermore the study was approvedby the Independent Ethics Committee of the Medical
Faculty Heidelberg (Ref. Nr.: S-170/2012).
Results
The median follow up for the entire cohort was 41 months
and 48 months in survivors (range 6 to 122 months). Only
three of the surviving patients had a follow-up interval of
less than 2 years. EBRT was completed in all patients with-
out treatment breaks >3 days. 76% of the patients received
at least 80% of the scheduled chemotherapy.
Local and regional control
We observed 4 local recurrences after 7, 14, 20 and
34 months of follow up. All local recurrences were located
inside the boost areas. The resulting estimated 1-, 3- and
5-years local control (LC) rates were 98%, 90% and 90%,
respectively (Figure 2). In the subgroup of patients with
stage III/IV disease, the 5-year LC rate was 89%. Of the four
patients with local recurrences, one was successfully
salvaged by surgery (alive without evidence of disease at last
follow up). One patient failed again after salvage surgery,
and 2 patients were treated with palliative chemotherapy.
One additional patient suffered from an isolated nodal
recurrence in the neck after 12 months, which was
located inside the radiation fields. The resulting esti-
mated 1-, 3- and 5-year regional control rates were
98%. The patient was successfully salvaged by neck
dissection (alive without evidence of disease at last
follow up).
Distant control, progression-free survival and overall survival
Distant metastases were observed in 6 patients after a
median time of 10 months. Three patients developed
Time [months]













Figure 4 Progression-free survival.
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first site of failure, one developed non-regional lymph
node metastases and two patients suffered from visceral
metastasis at multiple sites including lung and liver. The
resulting estimated 1-, 3- and 5-year distant control rates
were 92%, 86% and 86%, respectively (Figure 3). In the
subgroup of patients with stage III/IV disease, a 5-year
distant control rate of 80% was observed.
Overall disease progression was found in 10 patients, 4
of them developed isolated locoregional failures and 5 iso-
lated distant failures, whereas one patient suffered from a
combined locoregional and distant failure. The resulting
estimated 1-, 3-, and 5-year progression free survival rates
were 86%, 70% and 69%, respectively (Figure 4). For stage
III/IV patients, the 5-year progression free survival rate
was 59%.
Considering overall survival, we observed 10 deaths, in-
cluding one patient who died due to advanced testicular
cancer and one patient who died due to a non-treatment
related sepsis 9 months after the end of concurrent che-
moradiation. The resulting estimated 1-, 3-, and 5-year
overall survival rates were 96%, 82% and 79%, respectively
(Figure 5). For stage III/IV patients the 5-year overall sur-
vival rate was 73%.
Functional impairments prior to chemoradiation
treatment
Beside treatment-related toxicity, some patients showed
already disease-related alterations of physiological func-
tions at diagnosis or prior to chemoradiation treatment.
These were mainly caused by compression or direct in-
vasion of the primary tumor into adjacent structures
resulting for example in middle ear effusion with hearingTime [months]













Figure 3 Distant control.loss or cranial nerve palsy. For detailed information
about functional impairments prior to chemoradiation
see Table 3.
Acute toxicity
Mild to moderate acute toxicities were documented in the
majority of patients, mainly as hematological toxicity or
mucosa-related side effects. The main severe hematological
side effect (≥ grade 3) was leucopenia. The main severe
non-hematological side effect (≥ grade 3) was dysphagia
(28 patients, 57%). However, 18 of these patients had
received a prophylactical placement of a percutaneousTime [months]













Figure 5 Overall survival.
Table 3 Functional impairments prior to chemoradiation
treatment
Functional impairment n %
middle ear effusion 22 45
hearing loss 18 37
t-tube placement 13 27
CN impairment (III, IV, VI)* 9 18
CN impairment (other) 9 18
nasal obstruction 7 14
headache 5 10




impaired smell 2 4
impaired taste 2 4
CN: cranial nerve, *: including symptoms caused by impairment of the
corresponding muscles, °: other than impairment of motility (see CN
impairment), t-tube : inserted into tympanic membrane to restore ventilation
in case of middle ear effusion.
Table 4 Severe acute toxicity
Severe acute side effects grade ≥ 3 n %
non-hematological
dysphagia
including proph. PFT 28 57
excluding proph. PFT 10 32
stomatitis 8 16
nausea 4 8




infection (including FUO) 8 16
thrombopenia 1 2
anemia 1 2
(≥ grade III) n: number of patients,%: percentage, proph.: prophylactical, PFT:
percutaneous feeding tube, FUO: fever of unknown origin, some patients
developed more than one toxicity.
Table 5 Xerostomia
Xerostomia n %
grade 1 27 55
grade 2 10 20




grade 0-1 19 15
grade 2-3 11 4
According to Radiation Therapy Oncology Group (RTOG) criteria as subjectively
assessed by the patients.
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dysphagia because of the tendency to use an already placed
PFT for at least parts of the nutritional support regardless
from the real extent of their need. Considering only
the 31 patients without prophylactical placement of a
PFT, severe dysphagia was documented in 10 pts
(32%) only. For detailed information about severe acute
side effects see Table 4.
Late toxicity
The main documented late toxicity was xerostomia (see
Table 5). Severity of xerostomia tended to be higher in
patients with sparing of one parotid vs. patients where
both glands were attempted to be spared. In these
patients, the combined rate of grade 2 and 3 xerostomia
was 37%, compared to 21% in patients with sparing of
both glands, but this difference did not reach statistical
significance. The remaining documented late toxicities
are summarized in Table 6. The patient with severe tris-
mus was the only patient with the need for long term
support with a percutaneous feeding tube. Both patients
who developed severe hearing loss (requiring hearing
aids) had already suffered from reduced hearing function
prior to chemoradiation. One patient with hyposmia
prior to chemoradiation developed complete loss of
smell and taste. No temporal lobe necrosis has been
documented.
Discussion
Here we show in 49 consecutive patients over a 10 year
period suffering from primary nasopharyngeal cancer,
that encouraging local control (5-year LC 90%) and
overall survival (5-year OS 79%) rates can be achievedwith acceptable acute and limited late toxicities using
IMRT combined with concurrent but not adjuvant
platin-based chemotherapy. Despite the limitations of
retrospective analyses of single institutions our results are
in good accordance with other IMRT-series [11-14,21-23]
describing similar results regarding outcome and toxicity
(see Table 7).
IMRT has been shown to result in dosimetric advan-
tages compared to other radiation techniques in naso-
pharyngeal cancer cases [8-10], which theoretically
should lead to reduced late toxicity, especially in terms
of xerostomia. Accordingly, we observed limited rates of
xerostomia (combined grade 2/3 : 30%) in our analysis,
which seemed to be further reduced in patients with
sparing of both parotid glands, although this difference
was not statistically different. It should be noted that
scoring of xerostomia is controversial, especially in
retrospective series and comparisons of different reports
are compromised by applying different assessment strat-
egies and grading scales. This may have contributed to
Table 6 Late toxicity
Late toxicity All grades (%) Grade≥ 3 (%)
hearing loss 10 4
mucosal reaction 14 4
trismus 4 2
loss of taste 29 na
loss of smell 14 na
skin reaction 18 0
dysphagia 12 0
lymph edema 10 0
hoarseness 6 0
dry eye 6 0
other° 20 2
Excluding Xerostomia, scored according to CTCAE 3.0, na : not applicable
(maximum score according to CTCAE 3.0: grade II), °: includes one patient (2%)
with permanently reduced but stable renal function scored as grade 3 toxicity,
some patients developed more than one toxicity.
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57%) even considering only IMRT series [11,12,14,22,23].
Scoring of xerostomia can be further complicated due to
its possible changes over time [12,14,22-24]. Neverthe-
less, the present results are in good accordance with
prior reports of our group, which showed effective pro-
tection of parotid function measured by quantitative per-
technetat scintigraphy in head and neck cancer patients
treated with IMRT compared to other radiationTable 7 IMxRT series
IMRT Series
Author Lee et al. Wolden et al. Kam et al. Kwong
Year 2002 2006 2004 200
Institution UCSF MSKCC PWH QM
Region USA USA Hongkong Hongk
n 67 74 63 50
f/u 31 35 29 25
Stage III/IV 70% 77% 57% 100
sim. CHT 75% 93% 25% 68%
adj. CHT 75% 93% 0% 68%
TD 65-70 70 66 76
SD 2,12-2,25 2,34 o. CB 2 2,17
add. Boosts Br 40% CB 80% Br/3D 56% non
LC (year) 96% (4y) 91% (3y) 92% (3y) 96% (
RC (year) 98% (4y) 93% (3y) 98% (3y) n.r
DC (year) 66% (4y) 78% (3y) 79% (3y) 94% (
OS (year) 88% (4y) 83% (3y) 90% (3y) 92% (
n: number of patients, f/u: median follow up (months), sim.: simultaneous, adj.: adju
local control, RC: regional control, DC: distant control, OS: overall survival, y: year, Br
reported, UCSF: University of California San Francisco [12], MSKCC: Memorial Sloan-
Mary Hospital [13], NCC: National Cancer Center [21], RTOG: Radiation Therapy Onc
[23], DKFZ: Deutsches Krebsforschungszentrum (German Cancer Research Center).techniques [25,26]. Moreover, Kam et al. [24] observed a
significant reduction of observer rated xerostomia paral-
leled by a significant increase in stimulated parotid and
whole saliva flow rate in a meticulously performed ran-
domized comparison of IMRT vs. 2D-RT, although there
was no significant difference in patient reported out-
comes between the two arms. In contrast, Pow et al. [27]
found that the reduction of xerostomia also transferred
into improved quality of life in a similar comparison. In
summary, there is growing evidence that IMRT can lead
to decreased rates of severe xerostomia compared to
other radiation techniques by sparing dose to one or
both parotid glands, although careful patient selection
for sparing of both parotid glands seems mandatory and
the attempt has to be weighed against target coverage as
highlighted by reports on intraparotideal recurrences
[28].
IMRT also offers the opportunity to increase the frac-
tionation dose inside the boost area using an integrated
boost concept, while keeping the single dose below 2 Gy
in most organs at risk at the same time. Therefore many
investigators [12,13,21-23] used at least slightly increased
single doses (2.12-2.25 Gy) inside the boost area without
markedly increased total doses. Consistent with our
analysis, in which the majority of patients received a
single dose of 2.2 Gy in the boost area up to a total
dose of 66–70.4 Gy, those regimens were generally
well tolerated. In contrast, Bakst et al. [29] reportedet al. Tham et al. Lee et al. Peponi et al. Own data
6 2009 2009 2010 2012
H NCC RTOG0225 USZ DKFZ
ong Singapore USA Switzerland Germany
195 68 39 49
27 31 30 48
% 56% 59% 85% 72%
57% 83% 97% 100%
35% 83% 97% 0%
70 70 66-70 66-70,4
2,0-2,12 2,12 2,0-2,2 2,2
e Br 10% none none none
2y) 90% (3y) 93% (2y) 86% (3y) 90% (5y)
. n.r. 91% (2y) 89% (3y) 98% (5y)
2y) 89% (3y) 85% (2y) 85% (3y) 86% (5y)
2y) 94% (3y) 80% (2y) 85% (3y) 79% (5y)
vant, CHT: chemotherapy, TD: total dose, SD: single dose, add.: additional, LC:
: Brachytherapy boost, CB: concomitant boost, 3D: 3d-confomal boost, nr : not
Kettering Cancer Center [11], PWH: Prince of Wales Hospital [14], QMH: Queen
ology Group [22], USZ: Universitätsspital Zürich (University Hospital Zuerich)
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(3 patients, 12%) in a prospective trial of 25 patients
treated with single doses of 2.34 Gy in the boost area
to a total dose of 70.2 Gy. Two of the three patients
suffered from T4 tumors and the region of temporal lobe
necrosis was located inside the boost PTV or directly adja-
cent to it. Because no temporal lobe necrosis had been
observed in a prior series of patients treated at the same
institution with a single dose of 2.12 Gy, they concluded
that this regimen was not safe. However, integrated boost
concepts appear to result in superior dose distributions
compared to sequential IMRT boost concepts according
to a planning study [30], especially regarding the dose to
most other organs at risk. Taken together single doses of
up to 2.2 Gy inside the boost areas appear to be safe.
However, caution is mandatory due to the extreme narrow
therapeutic margin and patients with invasion of intracra-
nial structures might be not ideal candidates for this strat-
egy. For those patients, charged particles such as protons
or carbon ions could be beneficial because of their dosi-
metric advantages. A recent planning comparison from
our institution has shown improved target coverage and
pronounced sparing of organs for a 3-field spot scanning
intensity modulated proton technique vs. 9-field step and
shoot photon IMRT [31].
Despite the retrospective nature and limited patient
number of our analysis, the outcome of our patients
with locally advanced nasopharyngeal cancer treated
with IMRT and concurrent but not adjuvant chemother-
apy is comparable to the results published by other
groups using similar approaches with the addition of ad-
juvant chemotherapy cycles [11-13,21-23]. Irrespective
of the advances in radiation therapy technique, the
addition of chemotherapy had been a major step towards
improved overall outcome in locoregionally advanced
nasopharyngeal cancer as shown by several randomized
trials and meta-analyses [1-5,7,16]. While little contro-
versy exists about the benefit of chemotherapy applied
concurrently to radiation therapy, the value of additional
adjuvant chemotherapy has been debated extensively
mainly due to limited treatment compliance and sub-
stantial toxicity in several trials. For example, 45% of the
patients in the INT 0099 trial [1] did not receive all
planned adjuvant chemotherapy cycles and about one
third did not receive any. Moreover, in the remaining
patients receiving adjuvant chemotherapy 52% had grade
3/4 toxicities. Similar findings have been reported by
Wee et al. [2] and a limited compliance has been
observed also in RTOG 0225 [22], which used IMRT as
radiation therapy technique. Considering oncological
outcome, three randomized trials have been performed
to examine the benefit of adjuvant chemotherapy mainly
compared to radiation alone [6,32,33]. None of them
showed a benefit in terms of event-free or overallsurvival and two of them even failed to show a benefit in
distant control [6,32]. Moreover, the meta-analysis by
Baujat et al. [7], which in fact showed a survival benefit
in favour of adding chemotherapy to radiation therapy,
concluded that this benefit was attributable to the con-
comitant rather than to the adjuvant phase. Conversely,
a combined analysis [34] of 441 patients from two ran-
domized trials (NPC 9901 and NPC 9902), who had
received radiation therapy as sole treatment or com-
bined with concurrent and adjuvant chemotherapy,
found a significant beneficial impact of chemotherapy on
distant control which was attributed to the adjuvant
phase according to the subsequent multivariate analysis
[34]. According to this analysis, patients developed sig-
nificantly less distant metastasis if they received 3 or
more cycles of adjuvant chemotherapy compared to
those with 0–1 cycles, indicating a value for adjuvant
chemotherapy if adequate doses can be achieved [34]. Fi-
nally, the issue of adjuvant chemotherapy after chemora-
diation has been addressed by a recent prospective
randomized multicenter trial [17]. In this trial, more
than 500 patients with non-metastatic locally advanced
nasopharyngeal cancer were assigned to either concur-
rent chemoradiation using weekly Cisplatin followed by
three cycles of adjuvant chemotherapy with cisplatin/5-
fluorouracil or to concurrent chemoradiation alone. Pri-
mary endpoint was failure-free survival. Radiotherapy
was given with single doses of 2–2.27 Gy in 5 fractions
per week to a total dose of ≥66 Gy to the primary tumor
and 60–66 Gy to the involved neck areas. Different radi-
ation techniques were permitted including IMRT.
Compliance to radiation therapy and concurrent chemo-
therapy was similar in both arms, but 18% of the
patients scheduled for the adjuvant phase did not receive
adjuvant chemotherapy at all, 37% did not receive all
three cycles, 69% of the patients had treatment delays
and 42% experienced grade 3–4 toxicity during the adju-
vant phase. With a median follow up of 38 months, the
estimated 2-year rates of failure free survival did not dif-
fer significantly between the arms, nor did the estimated
2-year rates of locoregional failure free survival, distant-
failure free survival or overall survival. Treatment group
was also not a significant predictive factor for any of the
mentioned endpoints in the multivariable analysis. The
authors concluded, that adding three cycles of adjuvant
chemotherapy did not improve outcome compared to
chemoradiation alone. They discussed that acute toxic
effects during concurrent chemoradiation decreased the
tolerance of the patients to adjuvant chemotherapy caus-
ing the limited treatment compliance.
In summary, treatment recommendations towards the
benefit of adjuvant chemotherapy after concurrent che-
moradiation remain controversial. However, data from
numerous phase II trials indicate, that the benefit of
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ferent timing [35] and/or the use of more potent regi-
mens including taxanes [17]. High rates of treatment
compliance [36], with excellent rates of distant control
and overall survival [35] have been reported, using a
neoadjuvant approach with upfront chemotherapy fol-
lowed by concurrent chemoradiation. Given the poten-
tial advantages of a neoadjuvant approach [37], this
strategy seems promising and is currently evaluated in
several phase III trials.
Conclusion
IMRT with concurrent but not adjuvant platin-based
chemotherapy resulted in encouraging rates of local and
distant control, progression-free and overall survival
with acceptable rates of acute and limited rates of late
toxicity in patients with nasopharyngeal cancer. Using
an integrated boost concept with single doses of 2.2 Gy
in the boost areas appears to be safe and effective. Our
findings of a single institution in consecutive patients
treated from 1999 to 2008 are in good accordance with
other series with or without adjuvant chemotherapy.
Based on the available evidence, the value of additional
adjuvant chemotherapy appears to be limited. Future
directions might include neoadjuvant chemotherapy and
potentially the introduction of charged particles, a strat-
egy which needs to be investigated in controlled trials.
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